CRISPR gene editing used to create 'Ready-Made' cancer therapy
NCT ID NCT04035434
Summary
This study tested a new type of cell therapy called CTX110 for adults with B-cell cancers that have returned or not responded to other treatments. The therapy uses immune cells (T cells) from healthy donors that are modified using CRISPR gene-editing technology to target cancer. The main goals were to find a safe dose and see if the treatment could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU de Lille
Lille, 59000, France
-
Cedars Sinai
Los Angeles, California, 90048, United States
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Duke University
Durham, North Carolina, 27710, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Hôpital Saint Antoine
Paris, 75012, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Markey Cancer Center, University of Kentucky
Lexington, Kentucky, 40536, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Roswell Park Cancer Insitute
Buffalo, New York, 14203, United States
-
Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
University Hospital Würzburg
Würzburg, 97080, Germany
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Hamburg
Hamburg, 20148, Germany
-
University of Kansas
Westwood, Kansas, 66205, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23298, United States
-
Washington University
St Louis, Missouri, 63130, United States
-
Weill Cornell Medical College / New York Presbyterian Hospital
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.